TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06314386

Intervention type: OTHER
Group type: OTHER
Intervention: Systems Analysis and Improvement Approach for TB (SAIA-TB)
Description: The Systems Analysis and Improvement Approach for TB (SAIA-TB) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by clinic staff with support from study personnel in intervention clinics. Components of the intervention include TB cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally optimize TB screening, evaluation, diagnosis, TB preventive therapy and TB disease treatment initiation, successful treatment, and TB-free survival among the population at the intervention clinics.
Study: NCT04722900

Intervention type: OTHER
Intervention: intrauterine exposure to elevated glucose levels
Description: intrauterine exposure to elevated glucose levels
Study: NCT05632523

Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion

Intervention type: OTHER
Intervention: urinary sample
Description: Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
Study: NCT05428332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-Compartment Unloader Brace
Description: Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
Study: NCT06208657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib, Irinotecan, Temozolomide
Description: Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
Study: NCT06362850

Intervention type: OTHER
Group type: OTHER
Intervention: Tele-support
Description: via real-time audio-video connection through an experienced physician
Study: NCT06168097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis
Description: 1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: women with intraoperative and / or histopathology findings suggestive of endometriosis
Description: 1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis.
Study: NCT06025760

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness
Description: All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness
Description: All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
Study: NCT06536023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 SA.QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 SA.QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362 placebo
Description: IBI362 placebo SA.QW
Study: NCT06580496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier
Description: Mightier is a pediatric at-home intervention program that includes an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14. The program also uses physical materials including printed workbooks and conversation cards that focus on teaching additional Cognitive Behavioral Therapy (CBT)-based skills and concepts.
Study: NCT05200143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
Study: NCT06526260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Brief Exposure to Facial Expressions
Description: In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.
Study: NCT04988295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.
Study: NCT05950464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo ECG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT05355571

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LAB4 + Saccharomyces boulardii
Description: Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05930821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise Program (GEMS program)
Description: * Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.~* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and Stretching Program (FLEX-MS program)
Description: * Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.~* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention.~* Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program.
Study: NCT06408870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study: NCT05817656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: 3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
Study: NCT04384809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte rich platelet rich plasma
Description: Leukocyte rich platelet rich plasma will be obtained and prepared from a peripheral artery of the subject and then will be injected in the common extensor tendon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tenotomy
Description: Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
Study: NCT05635344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Single dose 200mg dose of Pembrolizumab given intravenously
Study: NCT06207786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Swabs
Description: Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Staphylococcus nasal swab
Description: Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Staphylococcus nasal swab
Description: Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization

Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotic
Description: Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
Study: NCT04637386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic wound infiltration
Description: 40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
Study: NCT05853016

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection for NEPHROCLEAR CCL14 Test
Description: Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection for NEPHROCLEAR CCL14 Test
Description: Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
Study: NCT06385769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: The TTNS will be conducted unilaterally, with the patient in a supine position, using a surface electrode dual stimulation channel stimulation device. Two self-adhesive round surface electrodes will be positioned with the negative electrode 2 cm behind the medial malleolus and the positive electrode 10 cm proximal to it. The ground electrode will be placed on the ipsilateral limb. Channel 1 will provide active stimulation, while channel 2 will remain inactive.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous tibial nerve stimulation (TTNS)
Description: Sham TTNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the TTNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
Study: NCT05594550

Intervention type: OTHER
Intervention: Data collection
Description: Demographic data:~Age, Sex, weight, height, main history and treatments.~- Biological data: CRP, PCT, albumin, pre-albumin

Intervention type: OTHER
Intervention: Data collection
Description: Demographic data:~Age, Sex, weight, height, main history and treatments.~- Biological data: CRP, PCT, albumin, pre-albumin

Intervention type: OTHER
Intervention: analysis of thoracic scans
Description: muscle area calculated on the T7 and T12 thoracic slices

Intervention type: OTHER
Intervention: analysis of thoracic scans
Description: muscle area calculated on the T7 and T12 thoracic slices
Study: NCT04808115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDS-1001
Description: Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle
Study: NCT05966454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple standard of care antibiotics for appendicitis, at physicians' discretion
Description: Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple standard of care antibiotics for appendicitis, at physicians' discretion
Description: Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
Study: NCT04935385

Intervention type: OTHER
Intervention: Collecting blood specimens
Description: Blood samples will be collected from all study participants at different required timelines
Study: NCT05357573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
Study: NCT05350722

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single dose ablative radiotherapy
Description: Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
Study: NCT06373016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: A glucose drink is administered midway through one of the scan sessions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketones
Description: A ketone drink is administered midway through one of the scan sessions.
Study: NCT05559177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric exosomal tumor vaccines
Description: Tumor cells (lesion site) were isolated from bladder cancer patients, and bladder cancer nuclei were extracted. Monocytes were isolated from peripheral blood of this patient and induced in vitro to obtain APC (DC or macrophage). Apc-tumor chimeric cells were constructed and stimulated with immune stimulator. Chimeric exosomal vaccines were extracted from cell supernatants by differential and hypervelocity centrifugation
Study: NCT05454735

Intervention type: PROCEDURE
Intervention: coronary artery bypass surgery
Description: coronary artery bypass surgery

Intervention type: PROCEDURE
Intervention: coronary artery bypass surgery
Description: coronary artery bypass surgery

Intervention type: PROCEDURE
Intervention: coronary artery bypass surgery
Description: coronary artery bypass surgery

Intervention type: PROCEDURE
Intervention: aortic valve replacement surgery
Description: aortic valve replacement surgery
Study: NCT06473727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnichoroma
Description: Patients with anterior non-carious cervical lesions were treated with Omnichoroma. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma Topaz One
Description: Patients with anterior non-carious cervical lesions were treated with Charisma Topaz One. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
Study: NCT05034146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: 68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: 68Ga-FAPI PET/CT scan were performed 20\~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
Study: NCT05026528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital diabetes self management education and support system
Description: Digital diabetes self management and support system
Study: NCT06066034

Intervention type: DIAGNOSTIC_TEST
Intervention: HOMA-IR，ESHRE/ASRM
Description: Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003

Intervention type: DIAGNOSTIC_TEST
Intervention: HOMA-IR，ESHRE/ASRM
Description: Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003

Intervention type: DIAGNOSTIC_TEST
Intervention: HOMA-IR，ESHRE/ASRM
Description: Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003